Three months after raising $500m in a series G round, Moderna Therapeutics has secured $125m as part of a collaboration agreement with Merck & Co.
US-based RNA-based vaccine developer Moderna Therapeutics has received $125m in series H funding from pharmaceutical firm Merck & Co as part of an expanded collaboration agreement.
Incubated by venture capital firm Flagship Ventures in 2010, Moderna is developing therapeutics and vaccines based on messenger RNA (mRNA) molecules that target cancer and infectious, rare and cardiovascular diseases.
Messenger RNA is a family of molecules that deliver genetic information from the DNA to the ribosome, where they control how cells synthesise proteins.
…
